Daniela Sieghart
Overview
Explore the profile of Daniela Sieghart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brinkmann M, Traby L, Kussmann M, Weiss-Tessbach M, Buchtele N, Staudinger T, et al.
Clin Immunol
. 2025 Mar;
274:110471.
PMID: 40044018
Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following...
2.
Vossen M, Kartnig F, Mrak D, Simader E, Stiasny K, Kain R, et al.
Wien Klin Wochenschr
. 2024 Oct;
136(21-22):598-607.
PMID: 39446203
Impaired immune response to COVID-19 (coronavirus disease 2019) vaccination has been reported in patients with inborn errors of immunity (IEI). Repetitive vaccinations are recommended for this vulnerable group. Due to...
3.
Van Hoovels L, Bakker-Jonges L, Vara D, Bijnens C, Studholme L, Sieghart D, et al.
Ann Rheum Dis
. 2024 Jul;
83(12):1793-1794.
PMID: 39043437
No abstract available.
4.
Sieghart D, Hana C, Durrschmid C, Heinz L, Haslacher H, Zlesak M, et al.
J Clin Virol
. 2024 Mar;
173:105661.
PMID: 38503118
Background: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population-based evidence on...
5.
Jorda A, Bergmann F, Ristl R, Radner H, Sieghart D, Aletaha D, et al.
Clin Microbiol Infect
. 2023 May;
29(9):1188-1195.
PMID: 37244466
Objectives: A weak correlation between symptom severity and antibody levels after primary immunization against COVID-19 has already been shown. This study aimed to describe the association between reactogenicity and immunogenicity...
6.
Sokolova M, Hartmann F, Sieghart D, Bang H, Steiner G, Kleyer A, et al.
RMD Open
. 2023 Jan;
9(1).
PMID: 36717186
Objective: Events triggering disease outbreak in individuals at-risk for rheumatoid arthritis (RA at-risk) remain unclear, and the role of the various anticitrullinated protein antibody (ACPA) isotypes in this process is...
7.
Mrak D, Kartnig F, Sieghart D, Simader E, Radner H, Mandl P, et al.
J Autoimmun
. 2023 Jan;
135:102981.
PMID: 36706534
Background: A 3 COVID-19 vaccination is currently recommended for patients under immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein has been...
8.
Sieghart D, Konrad C, Swiniarski S, Haslacher H, Aletaha D, Steiner G
Front Immunol
. 2023 Jan;
13:1096866.
PMID: 36685579
Objectives: Anti-citrullinated peptide antibodies (ACPA) are specific markers for rheumatoid arthritis (RA) and typically measured by assays employing a cyclic citrullinated peptide (CCP) as antigen. This study was aimed at...
9.
Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenohrl T, Zdravkovic A, et al.
Clin Microbiol Infect
. 2022 Dec;
29(5):635-641.
PMID: 36509374
Objective: To investigate the immunogenicity and safety of BNT162b2 booster vaccination with and without a tetravalent influenza vaccine. Methods: A prospective, open-label cohort study on immunogenicity and safety of COVID-19...
10.
Sieghart D, Hana C, Haslacher H, Perkmann T, Heinz L, Fedrizzi C, et al.
Clin Infect Dis
. 2022 Nov;
76(5):816-823.
PMID: 36328594
Background: An understanding vaccine-dependent effects on protective and sustained humoral immune response is crucial to planning future vaccination strategies against coronavirus disease 2019 (COVID-19). Methods: In this multicenter, population-based, cohort...